Profiel
Nathan Chen worked as the Director of Regional Clinical Development at Boehringer Ingelheim Corp.
He then served as the Head of Immunology & Inflammation at GSK Plc from 2018 to 2020.
Currently, he is the Vice President of Regulatory Affairs at LianBio.
Mr. Chen holds graduate degrees from Purdue University, Rensselaer Polytechnic Institute, and the State University of New York at Albany.
Eerdere bekende functies van Nathan Chen
| Bedrijven | Functie | Einde |
|---|---|---|
| LIANMEDICAL | Algemeen Adviseur | 01-02-2023 |
| GSK PLC | Corporate Officer/Principal | 01-02-2020 |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets health care products | Corporate Officer/Principal | - |
Opleiding van Nathan Chen
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Purdue University
Purdue University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rensselaer Polytechnic Institute
Rensselaer Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
State University of New York at Albany
State University of New York at Albany Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets health care products | Health Technology |
LianBio
LianBio BiotechnologyHealth Technology Operates as a biotechnology company focused on bringing paradigm-shifting medicines to patients | Health Technology |
















